3P Biopharmaceuticals increases its microbial production capacity with the installation of a 500 L fermenter. March 1, 2023 Read more >
3P Biopharmaceuticals brings together leading international experts in biomedicine to celebrate its 15th anniversary. December 1, 2022 Read more >
Osivax and 3P Biopharmaceuticals team up to develop a new universal vaccine against current and future variants of SARS-COV-2 November 26, 2022 Read more >
BrainEver and 3P Biopharmaceuticals collaborate on development of recombinant human homeoprotein Engrailed-1 November 15, 2022 Read more >
3P Biopharmaceuticals among the 100 best companies to work for in Spain September 27, 2022 Read more >
Biovian Announces the Appointment of a New Board Member − Dr. Uwe Gottschalk September 22, 2022 Read more >
3P Biopharmaceuticals celebrates its 15th anniversary with Juan Carlos Unzué. July 29, 2022 Read more >
3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis “Black Fungus” clinical phase II trial. July 11, 2022 Read more >
3P Biopharmaceuticals awards prize for the best Final Degree Project in Pharmacy at the University of Navarra June 24, 2022 Read more >
Dámaso Molero, appointed member of the Technical Committee of the Interdepartmental Commission for Personalized Medicine of Navarra. March 4, 2022 Read more >
ANLBIO selected Biovian for manufacturing of AAV-based product for the treatment of Alzheimer’s disease. February 18, 2022 Read more >
Elena Erroba, winner of the Navarra 2021 Management Award organised by AMEDNA-NEEZE November 17, 2021 Read more >
3P Biopharmaceuticals presents its growth plan at BIOSPAIN to further expand its operations in Europe and the USA September 29, 2021 Read more >
3P Biopharmaceuticals enters into alliance with Precirix to develop precision radiopharmaceuticals in oncology August 17, 2021 Read more >